Home NeedleSafe II Contact Other Inventions VersaPad PowerDesk O2ACE Sys Ingenious Technologies Corporation
 

Ingenious Technologies Corporation

O-ACE-Sys™ (Oxygen Augmented Controlled-Environment System; pronounced “Oasis”) is a patent-pending revolutionary wound care technology specifically designed to produce accelerated healing while sharply reducing cost. Chronic wounds represent a heavy burden to patients, health care professionals, and the US health care system, affecting 5.7 million patients and costing an estimated 20 billion dollars annually.. Wound care in general is mired in high cost and slow resolution due to a combination of factors, including:

  1. Increasing incidence of obesity, diabetes and peripheral vascular diseases. They not only predispose the body to skin breakdown, but also lessen its ability to heal its wounds due to inability to deliver adequate oxygen and circulation to injured tissue;

  2. The above triad is on a collision course with rising incidence of drug resistant organisms and a nearly dry pipeline of new antibiotics that can fight them.

  3. Increasing healthcare costs and chronic, worsening shortage of skilled nursing care. The result is that a wound gets suboptimal attention or intervention – typically only once every other day. This may include the application of a medicament (such as a paste of digestive enzymes to a necrotic wound to help remove non-viable tissue) or negative pressure (NPWT) wound dressing. Each change of dressing risks the introduction of contamination and “shear injury” (disruption of granulation tissue and newly-formed micro-vessels);

  4. Increasing number of sophisticated and challenging surgical procedures (such as reconstructive surgery and skin grafts) and increasingly complex and severe injury (such as a deeply contaminated wound from an IED [improvised explosive device]).

CDC statistics (June 2008) showed that diabetes affects nearly 24 million people in the United States, an increase of more than 3 million in approximately two years. In addition, 57 million are estimated to have pre-diabetes. The obesity epidemic is fueling the increase.

Foot ulcers will affect up to 25 percent of people with diabetes during their lifetime. People with diabetes have a 30-fold higher lifetime risk of undergoing a lower extremity amputation in comparison to those without diabetes. A foot ulcer precedes a lower extremity amputation 85 percent of the time.

Over 82,000 amputations of the lower leg were performed on diabetics in the US annually , representing many months, if not years of failed medical therapy with enormous burdensome morbidity and costs. Direct medical costs for diabetes and complications in the US was $92 billion in 2005.

In 2007, CMS (Center for Medicare & Medicaid Services) reported treating 257, 412 Stage III and IV pressure ulcers at an average charge per stay of $43,180 and a total cost of $11.1 billion. This hefty cost is only for severe chronic ulcers in Medicare patients ONLY and does not include non-Medicare patients or stage I & II chronic ulcers, nor does it include the cost of treating tens of millions of acute wounds which result from elective operations (over 24 million general anesthetics given annually in the US), or from trauma such as vehicular accidents or IED explosions from war.

O-ACE-Sys comprises a clear-view low-profile chamber that flexibly adheres to body surfaces to provide a controlled microenvironment optimized with a customizable therapeutic regimen. This low cost but high-value wound care system will sharply reduce the need for dressing changes AND – even more importantly – provide superior results at an accelerated rate previously not possible.

Download a PowerPoint presentation for more details.

Download wound care expert assessment of O-ACE-Sys from Stanford University Medical Center

Download wound care expert assessment of O-ACE-Sys from Venice Regional Medical Center

Download wound care expert assessment of O-ACE-Sys from the Cleveland Clinic

If you are a skilled healthcare executive, entrepreneur or angel investor interested in helping to commercialize this technology, please contact us via and provide detailed info how you propose to add value and create synergy.

O-Ace-SysO-Ace-Sys
Click thumbnail for a larger image

Home | Needlesafe II | O-Ace-Sys | PowerDesk | VersaPad | Other Inventions | Contact